Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$73.70
+0.30 (+0.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.2B · quality 82.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$18.3B
P/E
11.8x
↓EV/EBITDA
7.2x
↓ROE
21.5%
↑Gross Margin
57.7%
↑Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.4%
FCF CAGR
+13.6%
FCF margin
25.0%
FCF / Net income
1.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.45B · net income $1.56B · FCF $1.61B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.45B | $6.45B | $5.89B | $5.51B | $5.06B |
| Net Income | $1.56B | $1.56B | $1.45B | $1.13B | $1.09B |
| EBITDA | $2.36B | $2.36B | $2.13B | $1.66B | $1.62B |
| EPS | 6.26 | 6.26 | 5.82 | 4.53 | 4.40 |
| Gross Margin | 57.7% | 57.7% | 57.9% | 59.7% | 59.7% |
| Operating Margin | 26.4% | 26.4% | 23.6% | 25.0% | 24.3% |
| Net Margin | 24.2% | 24.2% | 24.6% | 20.5% | 21.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.26 | 0.32 | 0.33 |
| Current Ratio | 1.71 | 1.71 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.61B | $1.61B | $1.22B | $985.7M | $1.10B |
| Returns | |||||
| ROE | 21.5% | 21.5% | 21.5% | 19.0% | 19.3% |
| Valuation | |||||
| P/E | 11.77 | 11.77 | 12.56 | 17.70 | 18.61 |
| EV/EBITDA | 7.23 | 7.23 | 8.09 | 11.64 | 12.30 |
| P/B | 2.54 | 2.54 | 2.70 | 3.36 | 3.60 |
| Growth & Yield | |||||
| Revenue Growth | 9.5% | 9.5% | 7.1% | 8.8% | — |
| EPS Growth | 7.6% | 7.6% | 28.5% | 3.0% | — |
| Dividend Yield | 6.1% | 6.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
1.5%
EPS terminal req.
$6.54
Spread vs growth
6.1%
5Y implied EPS CAGR
4.8%
EPS terminal req.
$7.91
Spread vs growth
2.8%
10Y implied EPS CAGR
7.4%
EPS terminal req.
$12.74
Spread vs growth
0.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.7%
Start / end P/E
13.0x → 11.8x
EPS bridge
5.82 → 6.26
Residual
-0.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.